Our top pick for
Beginners

Oramed Pharmaceuticals Inc is a biotechnology business based in the US. Oramed Pharmaceuticals shares (ORMP) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
Latest market close | $4.56 |
---|---|
52-week range | $3.59 - $31.54 |
50-day moving average | $5.00 |
200-day moving average | $13.17 |
Wall St. target price | $31.67 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.00 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.56 from 2022-06-28
1 week (2022-06-22) | 7.80% |
---|---|
1 month (2022-05-27) | -7.13% |
3 months (2022-03-28) | -49.78% |
6 months (2021-12-29) | -65.19% |
1 year (2021-06-29) | -65.92% |
---|---|
2 years (2020-06-29) | 30.66% |
3 years (2019-06-28) | 27.02% |
5 years (2017-06-29) | 7.63 |
Revenue TTM | $2.7 million |
---|---|
Gross profit TTM | $2.7 million |
Return on assets TTM | -14.8% |
Return on equity TTM | -25.66% |
Profit margin | 0% |
Book value | $4.21 |
Market capitalisation | $189 million |
TTM: trailing 12 months
We're not expecting Oramed Pharmaceuticals to pay a dividend over the next 12 months.
Oramed Pharmaceuticals's shares were split on a 1:12 basis on 22 January 2013. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oramed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Oramed Pharmaceuticals shares which in turn could have impacted Oramed Pharmaceuticals's share price.
Over the last 12 months, Oramed Pharmaceuticals's shares have ranged in value from as little as $3.59 up to $31.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oramed Pharmaceuticals's is 2.029. This would suggest that Oramed Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.